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ABSTRACT
Study objectives were to compare the numbers of lym-
phocytes and lymphocyte subpopulations in induced
sputum from asthmatic patients and from healthy 
subjects, and to determine the effect of inhaled anti-
asthmatic steroid therapy on these cell numbers.
Hypertonic saline inhalation was used to non-invasively
induce sputum samples in 34 patients with bronchial
asthma and 21 healthy subjects. The sputum samples
were reduced with dithioerythritol and absolute
numbers of lymphocytes and lymphocyte subpopula-
tions were assessed by direct immunofluorescence and
flow cytometry. To assess the effect of beclomethasone
dipropionate (BDP) on induced sputum, numbers of
lymphocytes and lymphocyte subpopulations in sputum
also were evaluated after 4 weeks of BDP inhalation
treatment in seven asthmatic patients. An adequate
sample was obtained in 85.3% of patients with asthma
and in 79.2% of the healthy subjects. Induced sputum
from patients with asthma had increased numbers of
lymphocytes (P = 0.009); CD4+ cells (P = 0.044);
CD4+ cells-bearing interleukin-2 receptor (CD25;
P = 0.016); and CD4+ cells bearing human histocom-
patibility leukocyte antigen (HLA)-DR (P = 0.033).
CD8+ cells were not increased in asthmatic patients. In
patients treated with inhaled steroids, numbers of
lymphocytes, CD4+ cells, CD25-bearing CD4+ cells
and HLA-DR-bearing CD4+ cells in sputum decreased
from pretreatment numbers (P = 0.016, 0.002, 0.003
and 0.002, respectively). Analysis of lymphocytes in
induced sputum by flow cytometry is useful in assessing
bronchial inflammation, and activated CD4+ lympho-
cytes may play a key role in the pathogenesis of airway
inflammation in bronchial asthma.
Key words: bronchial asthma, CD4-positive lympho-
cyte, flow cytometry, induced sputum, interleukin-2
receptor.
INTRODUCTION
Asthma now is recognized as an airway inflammatory dis-
order. Knowledge of cellular mechanisms in the airways
of asthmatic patients has been increased by study of
specimens from bronchoalveolar lavage (BAL) and
mucosal biopsy.1–5 Eosinophils contribute to bronchial
inflammation by releasing granule-derived proteins and
inflammatory mediators.6–9 In addition to eosinophils, 
T cells may play a key role in the pathogenesis of
asthma,10–12 by producing several cytokines that modu-
late IgE production by B cells or induce migration and
activation of eosinophils.13,14
Performing fiber-optic bronchoscopy in patients with
asthma to obtain lavage or biopsy specimens sometimes
causes severe bronchoconstriction; in one study, 20% of
subjects experienced a fall in forced expiratory volume 
in 1 s (FEV1) of more than 40% after fiber-optic broncho-
scopy.15,16 Examination of sputum samples is a non-
invasive alternative method for studying mechanisms in
asthma. Eosinophils and metachromatic cells have been
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reported to be present in sputum from asthmatic patients.17
Pin and coworkers have described a sputum induction
method using hypertonic saline for studying airway inflam-
mation in these patients.18 Other authors have also found
sputum induction with hypertonic saline to be useful and
relatively safe in patients with asthma.19–21 Kidney et al.
have used flow cytometry to examine lymphocytes in
sputum and have confirmed the validity and reproduc-
ibility of lymphocyte measurements obtained by this
method.22
We hypothesized that induced sputum from asthmatic
patients would contain increased numbers of CD4+ lym-
phocytes and activated CD4+ lymphocytes, and also that
inhaled steroid therapy would decrease the number of
such cells in induced sputum. Flow cytometry was used to
study overall numbers of lymphocytes and cell numbers in
specific lymphocyte subpopulations in induced sputum
from asthmatic and healthy subjects. We also studied
numbers of lymphocytes and specific lymphocyte sub-
types in sputum before and 4 weeks after initiation of
inhaled steroid therapy to investigate the effect of the
treatment on airway inflammation.
METHODS
Subjects
Subjects recruited for the present study were non-smokers
between 20 and 75 years old. Patients seen at Kure
Kyosai Hospital between March 1995 and September
1996 who met the criteria for diagnosis of bronchial
asthma established by the National Heart, Lung and
Blood Institute of the US National Institutes of Health23
were evaluated. Thirty-four patients (16 women and 18
men, mean age 50.9 ± 13.4 years) were accepted as
candidates and underwent sputum induction by hyper-
tonic saline. Clinical and demographic features of
subjects with asthma are summarized in Table 1. Patients
with asthma were atopic as defined by the presence of
serum IgE specific to common aeroallergens (radio-
allergosorbent test; Pharmacia Diagnostics, Uppsala,
Sweden). Of the 34 patients with asthma, 28 were receiv-
ing treatment with an inhaled b 2-agonist, 30 with a
sustained-release theophylline preparation (daily dose
300–600 mg), eight with inhaled beclomethasone 
dipropionate (BDP; daily dose 200–800 m g), 11 with
prednisone (daily dose, 2.5–40 mg), two with pranlukast
hydrate (daily dose 450 mg), one with ketotifen fumarate
(daily dose 2 mg), one with ozagrel hydrochloride (daily
dose, 400 mg) and one with pemirolast potassium (daily
dose, 20 mg). Normal control subjects (nine women and
12 men, mean age 46.2 ± 14.7) were healthy volun-
teers with no history of allergy or asthma. To assess the
effect of BDP on induced sputum, seven of the patients
with asthma (four women and three men, mean age
64.4 ± 6.4 years; cases 3, 5 and 25–29 in Table 1)
were assessed both before and 4 weeks after BDP inhala-
tion treatment. For at least 3 months preceding the first
assessment of induced sputum, none of these seven
patients had received any treatment with BDP. After the
first assessment, the subjects underwent inhalation treat-
ment with BDP (800 m g/day for 4 weeks), followed by a
second assessment. Informed consent was obtained from
all subjects. The study was approved by the ethics com-
mittee of Kure Kyosai Hospital.
Induction of sputum
Induction of sputum was carried out in the emergency
room of Kure Kyosai Hospital with close monitoring by a
physician investigator. Peak expiratory flow (PEF) was
measured using an Assess peak flow meter (Healthscan
Products, Ceder Grove, NJ, USA) before inhalation of
hypertonic saline. Patients complaining of wheezing or
dyspnea were treated with 30 mg of procaterol hydro-
chloride by inhalation prior to any saline exposure.
Patients with wheezing or dyspnea even after procaterol
hydrochloride treatment did not proceed to further steps.
Subjects were instructed to rinse their mouths and throats
with fresh water just before beginning inhalation of nebu-
lized saline and every 15 min thereafter. Subjects inhaled
3% saline for 60 min via a nebulizer (NE-C11, Omron,
Tokyo, Japan) between 9.00 and 10.00 hours. In a pre-
liminary study, we could not obtain a sufficient amount of
sputum in some cases using less than 30 min of induc-
tion. Inhalation of hypertonic saline for 60 min, in
contrast, yielded appropriate sputum samples in most
cases. We chose 60 min as the duration of sputum induc-
tion. The nebulizer used generates particles with a mean
mass median diameter of 10 m m, amounting to an
output of 0.3 mL/min. When patients complained of
dyspnea or if the physician investigator noted wheezing
during inhalation of hypertonic saline, the sputum induc-
tion procedure was stopped immediately and subjects
then were treated with procaterol hydrochloride. Subjects
expectorated saliva and rinsed their mouths just before
coughing up sputa. Sputa were collected in a container
and kept on ice.
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Processing of sputum cells
Sputum was diluted approximately 40-fold with phosphate-
buffered saline (PBS) containing 0.01 mol/L dithioery-
thritol (Sigma Chemical Co., St Louis, MO, USA) and
0.1% sodium azide. Diluted sputa were shaken for 2 h on
ice and then passed through a cell strainer (Becton
Dickinson Labware, Franklin Lakes, NJ, USA) to remove
unsolubulized sputum components and debris. Sputum
cells were centrifuged at 900 g for 20 min at 4°C. Cells
were washed twice with PBS and resuspended in 1 mL of
PBS containing 2.5% bovine serum albumin (Sigma
Chemical Co.) and 0.1% sodium azide. During the
course of processing, cells were kept at 4°C.
Measurements
Primary outcome measurements
Specific binding of monoclonal antibodies was analyzed by
direct immunofluorescence using a two-color combination
of fluorescein isothiocyanate (FITC) and phycoerythrin (PE).
Negative control samples of cells incubated with isotype-
matched irrelevant FITC- and PE-labeled monoclonal
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Table 1 Characteristics of patients with asthma
Case no. Gender Age IgE (RAST score) Type %PEF Severity Age at onset Duration Medications
HD DF (years) of symptoms
1 F 49 2 2 A 98.7 Severe 48 12 mo B,T,I,P
2 F 40 < 1.0 < 1.0 NA 61.4 Moderate 30 10 yr B,T
3 F 55 < 1.0 < 1.0 NA 26.0 Severe 54 1 yr B
4 M 50 2 < 1.0 A 83.7 Intermittent 50 1 mo B,T,P
5 F 68 4 4 A 73.5 Moderate 64 4 yr B,T
6 F 61 < 1.0 < 1.0 NA 70.5 Severe 55 6 yr B,T,I,P
7 M 26 ND ND ND ND Moderate 10 16 yr B
8 M 28 ND ND ND 83.9 Mild 7 16 yr B,T,K
9 M 52 4 4 A 78.8 Moderate 49 3 yr B,T,I
10 F 54 ND ND ND 88.7 Mild 33 21 yr T,I
11 F 60 2 2 A 39.6 Severe 32 28 yr B,T,P
12 F 37 6 6 A 29.0 Severe 21 16 yr B,T
13 F 46 < 1.0 < 1.0 NA 25.6 Severe 37 9 yr B,T,I,P
14 M 68 < 1.0 < 1.0 NA 87.9 Severe 15 5 yr B,T,P
15 M 37 ND ND ND 117.8 Severe 20 18 yr B,T,P
16 M 46 < 1.0 < 1.0 NA 102.2 Mild 45 13 mo T,I
17 F 53 3 4 A 88.9 Intermittent 52 13 mo T
18 M 61 4 4 A 38.6 Severe 34 27 yr B,T,P,Pe
19 F 48 < 1.0 < 1.0 NA 28.6 Severe 27 21 yr B,T,I,Pr
20 F 42 ND ND ND 98.5 Intermittent 42 3 mo B
21 M 64 < 1.0 < 1.0 NA 81.2 Mild 62 18 mo B,T
22 M 45 < 1.0 < 1.0 NA 69.8 Severe 39 6 yr B,T,P
23 F 63 < 1.0 < 1.0 NA 100.3 Mild 63 3 mo B,T,Pr
24 F 55 < 1.0 < 1.0 NA 84.0 Mild 52 3 yr T,O
25 F 64 < 1.0 < 1.0 NA 71.1 Moderate 59 5 yr T
26 M 69 4 4 A 69.0 Severe 28 41 yr B,T,P
27 F 69 < 1.0 < 1.0 NA 100.3 Mild 64 5 yr B,T
28 M 70 < 1.0 < 1.0 NA 43.1 Severe 42 28 yr B,T
29 M 56 5 5 A 74.2 Moderate 11 46 yr B,T
30 M 40 3 4 A 114.2 Intermittent 38 2 yr B
31 M 24 5 5 A 96.5 Mild 24 3 mo B,T
32 M 36 5 5 A 63.9 Moderate 33 3 yr B,T,I
33 M 63 5 4 A 87.3 Mild 56 7 yr T
34 M 29 5 5 A 133.6 Intermittent 27 2 yr B,T,P
HD, house dust; DF, Dermatophagoides farinae; A, atopic; NA, non-atopic; ND, not determined; PEF, peak expiratory flow; yr, years; mo, months;
B, inhaled beta-agonist; T, theophylline; I, inhaled beclomethasone dipropionate; P, prednisone; K, ketotifen fumarate; O, ozagrel hydrochloride; 
Pe, pemirolast potassium; Pr, pranlukast hydrate.
antibodies were included in each run. Briefly, 100 m L
aliquots of sputum cell suspension were incubated with
10 m L of relevant FITC- or PE-labeled antibody for 30 min
in the dark on ice. The following two-color combinations
(FITC/PE) were used: CD8/CD4, CD25/CD4, human
histocompatibility leukocyte antigen (HLA)-DR/CD4 and
CD45/CD14 (Ortho Diagnostic Systems, Raritan, NJ,
USA). After cells were washed once, two-color immuno-
fluorescence analysis was performed with a Cytoron
Absolute flow cytometer (Ortho Diagnostic Systems). An
appropriate gate was drawn around the lymphocyte pop-
ulation, as defined by forward scatter and side scatter
characteristics in the peripheral blood.
CD45, also known as the leukocyte common antigen,
is a surface glycoprotein expressed on cells of all hemato-
poietic lineages except for mature erythrocytes. CD14 is
expressed on monocytes, macrophages and activated
granulocytes. Cell populations that were CD45 positive
and CD14 negative were defined as lymphocytes.
Amounts of contaminating monocytes, macrophages
and debris in sputum were estimated by this combination
of CD14 and CD45. In most samples, we found sufficient
numbers of lymphocytes for study and small numbers of
monocytes or macrophages. For samples in which the
amount of contamination within the lymphocyte-related
gate interfered with analysis of lymphocyte subpopula-
tions, all data were discarded. Absolute lymphocyte
count was performed using the Ortho-Count Calibration
Kit (Ortho Diagnostic Systems). The cytometer used
delivers precise volumetric aliquots of samples for analy-
sis. The volume delivered can be calibrated so that
accurate and precise absolute cell subset determinations
can be made. Briefly, four microparticle suspensions were
used to calibrate and verify the counting functions of the
cytometer. The constant flow rate was calibrated from 
the known number of particles per unit volume; then the
counts in the other three suspensions were determined to
verify calibration and counting linearity.24 We used this
method to study the absolute number of lymphocytes,
CD4+ cells, CD25-bearing CD4+ cells, HLA-DR-bearing
CD4+ cells and CD8+ cells. Positive cells were calculated
excluding non-specific staining and assessed using isotype
control antibodies directed against an irrelevant antigen.
Secondary outcome measurements
Differential cell counts were performed on cytocentrifuge
preparations using cell suspension and centrifugation 
at 300 g for 10 min. After fixation in 99.5% ethanol 
solution for 5 min, sputum samples were air dried and
stained with May-Giemsa. More than 400 cells were
counted by scanning several fields of view. Samples con-
taining more than 10% squamous cells were considered
inadequate and discarded.
Statistical analysis
All data are presented as the mean ± SD. Student’s t-test
was used to assess the differences between healthy and
asthmatic subjects. Cell counts before and after treat-
ment with BDP inhalation were compared using a paired
t-test; P values less than 0.05 were considered statistically
significant.
RESULTS
Safety and success of the method
In two patients with asthma, inhalation of saline caused
slight wheezing that subsided quickly after inhalation of a
bronchodilator. Of the 34 patients with asthma, ade-
quate samples were obtained from 29 patients (16
women and 13 men, mean age 53.1 ± 12.1 years) 
corresponding to cases 1–29 in Table 1. Samples were
inadequate in the five other patients with asthma
(14.7%). Of the 21 healthy subjects, adequate samples
were obtained from 16 (seven women and nine men,
mean age 46.3 ± 15.8 years), while five (23.8%) had
inadequate samples.
Comparison of lymphocytes and lymphocyte
subpopulations between patients with asthma
and healthy subjects
Direct immunofluorescence and flow cytometry were
used to quantitate lymphocytes and lymphocyte subpop-
ulations in sputum samples. As shown in Table 2,
absolute numbers of lymphocytes, CD4+ cells, CD25-
bearing CD4+ cells and HLA-DR-bearing CD4+ cells
were significantly higher in induced sputum from patients
with asthma than from healthy subjects. However, the
number of CD8+ cells in induced sputum from patients
with asthma was not significantly higher than in healthy
subjects.
Changes in lymphocyte profile in induced
sputum after treatment with inhaled BDP
Four weeks after starting BDP inhalation, significant
decreases were noted for several cell types: the number
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Table 2 Cells in induced sputum from healthy subjects and patients with asthma
Patient no. Squamous cell Differential cell count Cell count
contamination (%) Lym. (%) Mac. (%) Eos. (%) Neu. (%) Lym.* CD4† CD25/CD4‡ HLA-DR/CD4§ CD8
(· 104) (· 104) (· 104) ( · 104) (· 104)
Healthy subjects
1 0.8 3.3 44.4 0.0 52.3 1.39 1.08 0.18 0.53 0.23
2 0.9 1.6 25.2 3.5 69.7 2.72 1.65 0.17 0.74 0.79
3 0.7 3.1 38.3 3.6 55.0 5.49 3.75 0.27 2.05 0.94
4 1.5 0.6 62.1 2.8 34.5 0.23 0.18 0.05 0.13 0.04
5 8.6 1.4 60.2 2.1 36.3 1.18 0.23 0.10 0.16 0.18
6 1.7 1.3 38.8 0.7 59.2 5.21 2.15 0.62 0.72 0.61
7 3.0 0.8 30.6 4.4 64.2 2.27 1.12 0.16 0.59 0.19
8 2.1 3.0 73.7 0.0 23.3 2.43 1.29 0.40 0.91 1.14
9 4.2 1.6 39.6 1.5 57.3 1.28 1.12 0.45 0.61 0.12
10 2.3 1.7 34.3 0.4 63.6 6.75 2.60 0.74 0.86 2.77
11 0.2 1.9 31.8 3.7 62.6 3.00 2.29 0.56 1.57 0.68
12 0.4 2.1 40.8 1.8 55.2 6.05 4.84 0.97 2.65 0.91
13 4.5 1.9 61.0 2.1 35.0 1.94 1.24 0.41 1.02 0.16
14 0.8 2.3 59.1 0.7 37.9 14.05 5.15 1.03 2.25 1.58
15 4.3 2.5 64.3 1.0 32.2 3.55 1.70 0.10 0.80 0.15
16 9.0 0.6 19.3 0.0 80.1 0.23 0.13 0.01 0.05 0.03
Mean 2.8 1.9 45.2 1.8 51.2 3.61 1.91 0.39 0.98 0.66
SD 2.7 0.8 16.0 1.5 16.0 3.44 1.53 0.32 0.77 0.73
Patients with asthma
1 1.0 2.9 5.3 86.0 5.8 15.49 5.69 0.34 3.19 4.19
2 1.0 0.9 3.7 65.5 30.0 1.08 0.62 ND 0.45 0.14
3 4.7 1.8 16.3 49.4 32.6 10.55 2.84 0.97 1.76 2.03
4 0.6 2.5 50.1 28.1 19.3 5.35 3.16 1.07 2.14 0.40
5 0.6 1.3 29.6 64.7 4.3 9.28 2.32 0.52 1.31 0.53
6 0.5 2.8 12.9 15.8 68.6 7.56 7.17 2.38 6.47 0.23
7 4.3 2.5 17.6 36.6 43.3 9.73 2.67 0.81 2.04 0.18
8 2.9 1.5 62.6 10.5 25.4 2.55 1.60 0.34 1.08 0.43
9 2.0 1.4 32.0 17.5 49.1 3.60 1.53 0.41 0.99 0.29
10 0.5 1.4 33.6 58.9 6.1 1.74 1.47 0.44 1.18 0.19
11 0.5 1.2 39.3 24.9 34.6 4.38 1.70 0.24 1.15 0.60
12 0.2 2.2 2.6 54.6 40.5 34.98 5.20 0.81 3.01 3.91
13 0.6 1.5 35.4 13.7 49.4 7.35 1.02 0.33 0.65 0.64
14 0.7 1.5 7.4 6.8 84.3 9.35 2.03 0.62 0.98 5.79
15 1.1 2.4 49.5 2.8 45.2 46.32 11.68 0.97 4.60 8.06
16 0.7 3.0 64.8 9.5 22.6 37.50 19.26 4.64 9.57 5.33
17 0.9 4.0 15.8 57.6 22.5 13.40 6.67 2.68 2.06 1.13
18 1.2 1.0 10.0 41.9 47.0 10.40 6.19 1.91 3.92 1.30
19 0.2 1.7 14.0 49.2 35.1 11.24 3.35 1.12 2.46 1.48
20 1.5 5.0 82.1 8.2 4.7 12.10 5.32 1.06 2.13 1.97
21 0.1 5.1 23.3 55.1 16.5 52.53 27.91 5.81 18.93 13.15
22 0.1 2.3 6.0 26.2 65.5 61.41 25.20 5.27 11.69 14.71
23 5.8 1.2 11.8 53.2 33.8 5.27 1.75 0.55 1.07 0.55
24 1.8 2.8 8.4 54.2 34.6 15.82 2.47 0.92 1.29 0.35
25 4.4 2.1 66.5 17.3 14.1 2.98 1.43 0.44 0.91 0.48
26 3.7 2.1 12.5 52.9 32.5 3.60 1.39 0.32 0.82 0.29
27 8.8 0.6 13.8 19.3 66.3 3.36 1.42 0.80 1.07 1.31
28 5.6 3.9 10.2 72.6 13.2 21.61 4.37 0.83 3.67 2.02
29 2.4 2.6 12.9 20.8 63.7 8.29 4.48 1.07 2.58 0.39
Mean 2.0 2.2 25.9 37.0 34.8 14.79 5.58 1.34 3.21 2.49
SD 2.2 1.1 21.9 21.9 21.2 16.01 6.95 1.50 3.99 3.74
Lym., lymphocytes; Mac., macrophages; Eos., eosinophils; Neu., neutrophils. Cell population designations including slashes (/) indicate positivity
for both markers. *P = 0.009, †P = 0.044, ‡P = 0.016, §P = 0.033.
of lymphocytes decreased from 8.53 ± 6.54 to
3.89 ± 3.67 · 104 (P = 0.016); CD4+ cells decreased
from 2.60 ± 1.36 to 1.49 ± 1.34 · 104 (P = 0.0023);
CD25-bearing CD4+ cells decreased from 0.70 ± 0.28
to 0.29 ± 0.23 · 104 (P = 0.0026); and HLA-DR-
bearing CD4+ cells decreased from 1.72 ± 1.05 to
1.01 ± 0.99 · 104 (P = 0.0022). No significant changes
were noted in total number of cells, 4.47 ± 2.08 versus
2.44 ± 1.54 · 106, or CD8+ cells, 1.01 ± 0.77 versus
0.70 ± 0.85 · 104 (Table 3).
DISCUSSION
Several types of inflammatory cells, including eosino-
phils, mast cells, and T lymphocytes, have been
implicated in the chronic inflammatory process in the
airway in asthma.12,25 An increased number of activated 
T cells has been observed, not only in peripheral blood,11
but also in BAL fluid from patients with asthma.26
Increased numbers of CD25-positive cells also are found
in bronchial biopsy specimens from patients with
asthma.12 Robinson and coworkers have found that
asthma is associated with increased lymphocytic expres-
sion of mRNA for interleukin (IL)-2, IL-3, IL-4, and IL-5,
and for granulocyte–macrophage colony-stimulating
factor (GM-CSF).13 Interleukin-4, IL-5 and GM-CSF
support the survival, growth, differentiation and accumu-
lation of eosinophils, which release several mediators
and proteins that contribute to mucosal and bronchial
hyperresponsiveness.27
Inhalation of hypertonic saline aerosol is a well-known
stimulus causing bronchoconstriction in patients with
asthma.28,29 In two patients, inhalation of saline using the
present method caused slight wheezing that was con-
trolled by the inhalation of a b 2-agonist. Caution and
emergency treatment provisions are essential when non-
isotonic solutions are inhaled. Wong and Fahy have
recommended measurement of peak flow at regular
intervals during sputum induction procedures involving
hypertonic saline aerosols.28 In the present study, hyper-
tonic saline inhalation was carried out in our hospital’s
emergency room to facilitate management of any possi-
ble sudden attack of asthma. During sputum induction,
symptoms were monitored closely by a physician investi-
gator and the procedure was stopped if the patient
complained of wheezing or dyspnea.
Although we do not know the mechanisms by which
lymphocytes are recruited into sputum by hypertonic
saline inhalation, previous studies have concluded that
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this method of induction produces sufficient and approp-
riate sputum for cellular analysis.18,19,21,30 One important
aspect of obtaining a proper sample is exclusion of
saliva. We asked subjects to rinse their mouths thoroughly
just before coughing up sputum during the induction.
Although we tried to exclude salivary contamination as
much as possible, a certain number of squamous cells
was always observed in the induced sputum, suggesting
the presence of some saliva. More than 99% of the cells
in saliva reportedly are squamous cells;19 because the
sputum samples that we studied contained less than 10%
squamous cells, we are confident that the amount of
saliva was not sufficient to affect lymphocyte numbers.
Recognition of cells in a May–Grünwald-Giemsa
stained sputum smear with a light microscope is time-
consuming and sometimes difficult.30 Furthermore, the
differential count of lymphocytes in sputum can be as low
as 2%.17,18,21 Such factors impede accurate determination
of lymphocyte numbers in sputum by routine light
microscopy. The method that we describe here is the first
to allow easy and precise determination of absolute
numbers of lymphocytes and lymphocyte subpopulations
in sputum. Direct immunofluorescence is used for flow
cytometry with a count calibration kit. Pin and other
researchers have studied differential white cell counts in
induced sputum from healthy and asthmatic subjects,
finding an increased percentage of eosinophils in
samples from asthmatic patients but no significant differ-
ence in the percentage of lymphocytes (absolute numbers
were not determined).18,19 We used absolute number to
assess lymphocytes in sputum, because a differential
count of cells may not accurately depict actual changes
of cells in sputum. For example, in a differential count a
prominent increase of eosinophils in sputum could mask
an absolute increase of sputum lymphocytes, because the
eosinophils could misleadingly lower the differential
count of lymphocytes. The discrepancy in sputum lym-
phocyte numbers between previous reports and the
present study is as yet unexplained, but it may be related
to differences in methods used to assess lymphocyte
number or simply to the difficulty of counting cytologically
stained sputum lymphocytes by light microscopy. Differ-
ences in sputum induction and processing also may have
contributed to differences in lymphocyte numbers. In our
method, sputum was induced by inhalation of the same
concentration of saline (3%) for the same period (60 min)
by all subjects, and we analyzed all sputum induced
during the induction procedure instead of selecting
mucus plugs within the sputum for analysis.
CD25 is a useful marker of acutely activated lympho-
cytes; its expression is transient and disappears quickly in
the absence of continued stimulation.31 In contrast, HLA-
DR antigen is expressed late after antigen stimulation.
We found overall numbers of lymphocytes, as well as
CD4+ cells and activated CD4+ cells, to be increased in
sputa from patients with asthma compared with numbers
in sputa from healthy subjects. Our results complement
others demonstrating increased numbers of lympho-
cytes, CD4+ and CD8+ cells in bronchial biopsy
specimens from patients with asthma.12,32 In studies
where flow cytometry has been used to analyze BAL cells
from patients with asthma, increased expression of
CD25 among CD4+ cells, as well as degree of activa-
tion of CD4+ lymphocytes, correlated with severity of
symptoms and degree of bronchial hyperresponsiveness.
Kidney et al. have used flow cytometry to examine lym-
phocyte subpopulations in sputum, finding that sputa
from patients with asthma contains an increased propor-
tion of B lymphocytes and activated helper T cells.22
Although the difference was not statistically significant,
the number of CD8+ cells in patients with asthma was
higher than in healthy subjects in the present study.
Increased numbers and activation of CD8+ cells have
been described in BAL fluid from patients with intrinsic
asthma,26 but involvement of CD8+ cells in bronchial
asthma remains unclear.
Corticosteroids have several anti-inflammatory actions.
In addition to inhibition of cytokine production,33–36 these
agents inhibit expression of CD25 and rapidly reverse
induced CD25 expression by T lymphocytes in vitro.37
Inhaled corticosteroids have been shown to reduce
bronchial hyperresponsiveness and improve pulmonary
function in patients with asthma.38,39 In the present study,
the mean percentage PEF in seven patients with asthma
increased from 65.3 ± 24.0 to 82.2 ± 12.1 after 4
weeks of treatment with BDP inhalation, a difference that
was not statistically significant. Reductions in T cell
numbers and activation status in peripheral blood,
bronchial mucosa and BAL fluid after corticosteroid
therapy have been reported.11,40 Significant decreases in
numbers of lymphocytes, CD4+ cells and activated CD4+
cells observed in induced sputum following BDP treat-
ment are in agreement with these reports. In our study,
although the change was not significant, the total number
of cells in sputum was also reduced after 4 weeks of BDP
treatment. In this sense, the effect of BDP may not be
wholly specific to lymphocytes or lymphocyte sub-
populations in sputum.
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In summary, we have demonstrated the feasibility of
flow cytometry for analysis of lymphocytes and lympho-
cyte subpopulations in induced sputum samples. We
believe that further studies of pathophysiologic changes,
such as lymphocytic expression of mRNA for cytokines
and production of cytokines by lymphocytes in relation to
lymphocyte surface markers, are necessary to understand
the role of lymphocytes in the inflammatory process of
bronchial asthma.
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